share_log

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

Benzinga ·  Nov 13 01:05  · Ratings

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $30 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment